- All Drug Categories
- Home
- Anti-cancer Drugs
- Healthcare Products
- Medical Information
- Statement
Osimertinib is a third-generation EGFR-TKI targeted drug specifically designed for the treatment of EGFR mutation positive non-small cell lung ...
Osimertinib is a third-generation EGFR-TKI targeted drug mainly used for the treatment of EGFR mutation positive non-small cell lung cancer (NS...
Osimertinib, as a third-generation EGFR-TKI targeted drug, covers the full course management of EGFR mutation positive non-small cell lung canc...
The standard usage of Osimertinib is once daily oral administration of 80mg, but individualized adjustments need to be made based on the treatm...
Pralsetinib is an anti-tumor drug targeting RET gene mutations, mainly used to treat RET fusion positive non-small cell lung cancer and thyroid...
Pralsetinib is a highly selective RET inhibitor that exerts anti-tumor effects by targeting and inhibiting RET gene fusion and mutation, blocki...
卡博替尼(Cabozantinib)的用药时长取决于适应症类型和个体反应，通常需持续服用直至疾病进展或出现不可耐受毒性，仅在与纳武单抗联合治疗肾细胞癌时明确限定最长24个月。 1 单药治疗的持续时间 (1)甲状腺髓样癌：每日140mg持续口服，无固定用药月份限制。 (2)...
Cabozantinib is a multi-target tyrosine kinase inhibitor that has been approved by the FDA for the treatment of various malignant tumors, inclu...
Cabozantinib usually requires long-term use, and the specific duration of medication depends on the type of indication, treatment efficacy, and...
Cabozantinib, as a multi-target tyrosine kinase inhibitor, has shown significant efficacy in various cancer treatments, mainly manifested in ...
